16 completed. 4 Phase 2, 3 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
| Not applicable | 1 | Completed 1 |
Follow Microbicide Trials Network: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Couple User Preferences in Dual Purpose Prevention Products HIV Prevention, Contraception Behavior | Completed | Microbicide Trials Network | 400 | 2020-01-21 | 2022-10-13 | |
| Rectal Microbicide Acceptability, Tolerability and Adherence Placebo rectal insert, Placebo rectal suppository, Placebo rectal douche - HIV Prevention | Not applicable | Completed | Microbicide Trials Network | 217 | 2019-04-26 | 2023-01-20 |
| Microbicide/PrEP Acceptability Among Mothers and Male Partners in Africa Focus Group Discussion (FGD), In-depth Interview (IDI) - HIV Prevention | Completed | Microbicide Trials Network | 232 | 2018-05-31 | 2022-10-14 | |
| Assessment of ASPIRE and HOPE Adherence In-depth Interview (IDIs) or Focus Group Discussion (FGD) - HIV Prevention | Completed | Microbicide Trials Network | 302 | 2016-06-13 | 2022-10-13 | |
| Study of Dapivirine Vaginal Ring (VR) in Adolescents placebo ring, dapivirine ring - Human Immunodeficiency Virus | Phase 2 | Completed | International Partnership for Microbicides, Inc. | 96 | 2014-06-27 | 2022-10-24 |
| An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial (MTN-003) HIV Prevention | Completed | Microbicide Trials Network | 219 | 2012-12-01 | 2021-06-23 | |
| Safety and Adherence of a Non-medicated Intravaginal Ring (IVR) Non-medicated Intravaginal Ring - Healthy | Phase 2 | Completed | Population Council | 195 | 2011-05-01 | 2017-08-15 |
| HIV-1 Resistance at Screening for HIV Prevention Studies HIV | Completed | Microbicide Trials Network | 1074 | 2010-08-01 | 2021-06-21 | |
| Bone Mineral Density Substudy - An Ancillary Study to MTN-003 Emtricitabine/tenofovir disoproxil fumarate, Emtricitabine/tenofovir disoproxil fumarate placebo, Tenofovir disoproxil fumarate - HIV Infections | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 518 | 2009-11-01 | 2023-02-08 | |
| EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure) Pregnancy Related | Completed | Microbicide Trials Network | 873 | 2009-10-01 | 2021-06-21 | |
| Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet Tenofovir, HEC Placebo, Open label tenofovir tablet - HIV Prevention, HIV Infections | Phase 1 | Completed | CONRAD | 18 | 2009-09-01 | 2015-08-28 |
| Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women Emtricitabine/tenofovir disoproxil fumarate, Emtricitabine/tenofovir disoproxil fumarate placebo, Tenofovir disoproxil fumarate - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 5029 | 2009-08-01 | 2021-10-29 |
| Observational Study of HIV Infected Women Previously Enrolled in Other Microbicide Trials HIV Infections | Completed | Microbicide Trials Network | 479 | 2008-08-25 | 2021-06-21 | |
| Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women Tenofovir disoproxil fumarate, Tenofovir gel - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 168 | 2008-06-01 | 2021-10-19 |
| Safety and Acceptability of SPL7013 Gel (VivaGelâ„¢) in Sexually Active Women 3% SPL7013 Gel (VivaGel), Placebo Gel, HEC Placebo Gel - Healthy | Phase 1 | Completed | Starpharma Pty Ltd | 61 | 2007-07-01 | 2010-06-24 |
| Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery Tenofovir 1% vaginal gel - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 21 | 2021-10-25 |
HIV Infections (6) · Acquired Immunodeficiency Syndrome (1) · Contraception Behavior (1) · HIV Seropositivity (1)
Tenofovir (5) · Emtricitabine (2) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (2) · Vaginal Creams, Foams, and Jellies (2) · hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenine (2) · astodrimer (1)
South Africa (9) · Uganda (9) · United States (8) · Zimbabwe (8) · Malawi (4) · India (1) · Peru (1) · Puerto Rico (1) · Thailand (1) · Zambia (1)
Alexandra Minnis, PhD (1) · Ariane van der Straten, PhD (1) · Ariane van der Straten, PhD, MPH (1) · Craig Hoesley, MD (1) · Craig W. Hendrix, MD (1) · Elizabeth Montgomery, PhD, MHS (1) · Ian McGowan, MD, PhD (1) · Jeanne Marrazzo, MD, MPH (1) · Richard Beigi, MD (1) · Richard Beigi, MD, MSc, FACOG (1) · Sharon A. Riddler, MD (1) · Sharon A. Riddler, MD, MPH (1) · Sharon Hillier, PhD (1) · Urvi Parikh, PhD (1)
PMID 21505316, PMID 21930612, PMID 22900504, PMID 22943559, PMID 23065145, PMID 23383037, PMID 23585827, PMID 25350119, PMID 25350130, PMID 25651245, PMID 25931240, PMID 25969178, PMID 26123563, PMID 26155597, PMID 26544581, PMID 26850270, PMID 27146827, PMID 27247202, PMID 27465646, PMID 28178109, PMID 28658251, PMID 29268654, PMID 29957723, PMID 30346511, PMID 30383589, PMID 30666522, PMID 30683103, PMID 31929401, PMID 32524700, PMID 33278181, PMID 33325126, PMID 33389318, PMID 35674885, PMID 38066471, PMID 38494656
U01AI068633 (4), UM1AI068615 (4), UM1AI068633 (4), UM1AI106707 (4), 5UM1AI068633 (2), 3UM1AI068633 (1)